Siddharth Mittal Takes the Helm as CEO of Syngene International to Drive Future Growth
On July 1, 2026, Siddharth Mittal officially stepped into his new role as the Managing Director and Chief Executive Officer of Syngene International, a significant player in the global contract research, development, and manufacturing organization (CRDMO) sector. His appointment follows the tenure of Peter Bains, who served until June 30, 2026. Siddharth brings extensive leadership experience that spans nearly three decades, with a noteworthy previous position as MD and CEO of Biocon Limited.
Siddharth’s impressive career at Biocon lasted throughout 13 years, during which he held pivotal positions including Chief Financial Officer before rising to the executive leadership role. His contributions at Biocon were substantial, steering the company toward long-term growth by enhancing commercial operations, expanding into international markets, and successfully launching its GLP-1 product portfolio. His efforts were also crucial in forming strategic partnerships and initiatives that reinforced Biocon's competitive edge, alongside emphasizing operational excellence and sustainable business practices.
In response to his appointment, Kiran Mazumdar-Shaw, Executive Chairperson of Syngene, expressed her satisfaction, stating: "I am delighted to welcome Siddharth as the Managing Director and CEO of Syngene. Having worked closely with him for many years, I understand his capabilities in navigating businesses through transitional phases. His strength in building robust teams and delivering transformational growth aligns perfectly with Syngene's current trajectory of evolution in the industry."
Syngene has established a strong reputation built on scientific excellence, quality service, and customer trust. As the organization stands on the verge of further development, Siddharth’s leadership is viewed as essential for unlocking the company's full potential. He is expected to harness his commercial insights and focus on execution to foster lasting value for customers, employees, and shareholders alike.
On stepping into his new role, Siddharth commented on the company’s established strengths: "I am honored to take on the role of Managing Director and CEO of Syngene. The firm has built remarkable scientific capabilities and has a competent team that has earned global trust. With these strengths, we have a solid foundation to pursue the next phase of sustainable growth. My immediate focus will be to enhance our commercial edge, promote delivery excellence, and foster discipline across all facets of the business."
Under Siddharth’s guidance, Syngene aims to combine rigorous scientific prowess with a dedicated workforce to elevate customer satisfaction and ensure cost-effectiveness. His objectives also include reviving growth trends and solidifying Syngene’s position as a global leader in CRDMO services, ultimately creating enduring value for all stakeholders.
Syngene International Ltd. (BSE 539268, NSE SYNGENE, ISIN INE 398R01022) is an integrated research, development, and manufacturing service provider catering to sectors like pharmaceuticals, biotechnology, and specialty chemicals. Employing over 8,300 individuals, including more than 5,700 scientists, Syngene is geared towards delivering scientific excellence and retaining the highest data security across its operations. The company operates extensive facilities across India and the U.S. and collaborates with approximately 400 global customers, including renowned organizations like BMS, GSK, Zoetis, and Merck KGaA. To explore more about their offerings and recent Environmental, Social, and Governance (ESG) efforts, visit Syngene's official site.
Siddharth’s impressive career at Biocon lasted throughout 13 years, during which he held pivotal positions including Chief Financial Officer before rising to the executive leadership role. His contributions at Biocon were substantial, steering the company toward long-term growth by enhancing commercial operations, expanding into international markets, and successfully launching its GLP-1 product portfolio. His efforts were also crucial in forming strategic partnerships and initiatives that reinforced Biocon's competitive edge, alongside emphasizing operational excellence and sustainable business practices.
In response to his appointment, Kiran Mazumdar-Shaw, Executive Chairperson of Syngene, expressed her satisfaction, stating: "I am delighted to welcome Siddharth as the Managing Director and CEO of Syngene. Having worked closely with him for many years, I understand his capabilities in navigating businesses through transitional phases. His strength in building robust teams and delivering transformational growth aligns perfectly with Syngene's current trajectory of evolution in the industry."
Syngene has established a strong reputation built on scientific excellence, quality service, and customer trust. As the organization stands on the verge of further development, Siddharth’s leadership is viewed as essential for unlocking the company's full potential. He is expected to harness his commercial insights and focus on execution to foster lasting value for customers, employees, and shareholders alike.
On stepping into his new role, Siddharth commented on the company’s established strengths: "I am honored to take on the role of Managing Director and CEO of Syngene. The firm has built remarkable scientific capabilities and has a competent team that has earned global trust. With these strengths, we have a solid foundation to pursue the next phase of sustainable growth. My immediate focus will be to enhance our commercial edge, promote delivery excellence, and foster discipline across all facets of the business."
Under Siddharth’s guidance, Syngene aims to combine rigorous scientific prowess with a dedicated workforce to elevate customer satisfaction and ensure cost-effectiveness. His objectives also include reviving growth trends and solidifying Syngene’s position as a global leader in CRDMO services, ultimately creating enduring value for all stakeholders.
Syngene International Ltd. (BSE 539268, NSE SYNGENE, ISIN INE 398R01022) is an integrated research, development, and manufacturing service provider catering to sectors like pharmaceuticals, biotechnology, and specialty chemicals. Employing over 8,300 individuals, including more than 5,700 scientists, Syngene is geared towards delivering scientific excellence and retaining the highest data security across its operations. The company operates extensive facilities across India and the U.S. and collaborates with approximately 400 global customers, including renowned organizations like BMS, GSK, Zoetis, and Merck KGaA. To explore more about their offerings and recent Environmental, Social, and Governance (ESG) efforts, visit Syngene's official site.
Topics Business Technology）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.